[15] For adults with community-acquired bacterial pneumonia, the most common side effects include nausea, increased levels of hepatic enzymes, vomiting, diarrhea, headache, rash, insomnia, abdominal pain, vein inflammation (phlebitis), high blood pressure and dizziness.

[15] For children with community-acquired bacterial pneumonia, the most common side effects include vomiting, headache, increased levels of hepatic enzymes, diarrhea, infusion site reaction, vein inflammation (phlebitis) and fever.

For Gram-negative pathogens, ceftobiprole has shown good in vitro activity against Haemophilus influenzae (including both ampicillin-susceptible and ampicillin-non-susceptible isolates), Pseudomonas aeruginosa and strains of Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis that do not produce extended-spectrum β-lactamases.

[20] The efficacy of ceftobiprole has been demonstrated in two large randomized, double-blind, phase III clinical trials in patients with hospital-acquired and community-acquired pneumonia.

[25] The efficacy of ceftobiprole medocaril in treating Staphylococcus aureus bloodstream infections (bacteremia) was evaluated in a randomized, controlled, double-blind, multinational, multicenter trial.

[15] Early clinical response required a reduction of the primary skin lesion by at least 20%, survival for at least 72 hours and the absence of additional antibacterial treatment or unplanned surgery.

[15] The efficacy of ceftobiprole medocaril in treating adults with community-acquired bacterial pneumonia was evaluated in a randomized, controlled, double-blind, multinational, multicenter trial.

[15] The US Food and Drug Administration (FDA) granted the application for ceftobiprole medocaril priority review, fast track, and qualified infectious disease product designations for the community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, and Staphylococcus aureus bloodstream infections (bacteremia) indications.